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Prior to registration, new medicines have 
demonstrated to adequately treat or pre-
vent diseases based on established efficacy 
and acceptable safety data in clinical tri-
als. Usually, the registration file for a new 
medicine (i.e., brand- name drug) contains 
clinical efficacy and safety trials or refer-
ences to such trials, both premarketing 
and postmarketing. Due to the presence of 
these efficacy and safety data in the regis-
tration file for a brand- name drug, health-
care providers sometimes tend to have 
more trust in the brand- name drug than 
in a generic drug, because the latter seems 
to be supported only by a limited amount 
of drug exposure data in healthy subjects.1 
However, the drug’s efficacy and safety ac-
tually are largely the characteristics of the 
active substance(s) rather than that of the 
drug product. Therefore, if two drug prod-
ucts contain the same active substance(s) in 
a qualitatively and quantitatively manner 
and have comparable exposure, they are ex-
pected to reach the same efficacy and safety 
in treating or preventing the target disease. 
In light of this knowledge, a so- called ge-
neric drug containing the same active sub-
stance(s) at the same dose is allowed to be 
marketed without efficacy and safety clini-
cal trials after the exclusivity of the brand- 
name drug expired. Instead, in most cases 
a bioequivalence study between the brand- 
name drug and the generic drug is suffi-
cient and serves to demonstrate that there 
is no impact of excipients and different 
manufactory processes of the generic drug 
on the pharmacokinetics (PKs) of the ac-
tive substance(s). In case demonstration of 
bioequivalence is complex (e.g., for drugs 
with controlled release or drugs with nar-
row therapeutic index) or not possible (e.g., 
for locally acting drugs), in most cases, the 
requested comparative studies still are less 
extensive than the clinical data requested 
by regulatory authorities for a brand- name 
drug. Because of this abridged regulatory 
requirement, generic drugs are competitive 
in price, and from that perspective more 
suitable to healthcare systems than the 
brand- name drugs. However, because of 
the lack of actual clinical efficacy and safety 
data for generic drugs, patients, patient’s 
organizations, and healthcare providers 
sometimes have concerns about generic 
drugs (i.e., these may not be as effective/
safe as the brand- name drugs).2
In practice, an adverse event (AE) re-
ported after switching from the brand- 
name drug to a generic drug are often 
ascribed to the generic drug.2 AEs are re-
ported more frequently in the period when 
a new generic drug enters the market or, in 
case the sale of a generic drug is strongly 
increased, whereas the incidence of the 
reported AEs some time after switching is 
usually comparable with that of the brand- 
name drug.3 However, the observation of 
an AE cannot be a priori considered evi-
dence for the assumption that the generic 
drugs perform worse than the brand- name 
drugs with regard to safety. The perception 
of issues toward generics differs among dif-
ferent stakeholders; a survey published by 
Colgan et al.4 investigated concern about 
generic drugs in the Netherlands. They 
found that patients mostly have concerns 
about the effectiveness of the generic drugs, 
pharmacists about the quality of the drugs, 
whereas doctors mostly have concerns 
about the safety of the drugs.
In response to the public concerns 
about generic drugs, it is considered im-
portant for regulatory authorities to verify 
whether the concerns bear value, also to 
verify whether the current requirements 
for generic drug approval with respect to 
bioequivalence are still sufficient to guar-
antee therapeutic equivalence between the 
generic drug and the brand- name drug, and 
to consider if any actions could be taken 
to resolve the concerns. For that purpose, 
in the past years, the Dutch regulatory 
authority (Medicines Evaluation Board) 
aims to provide explanations, supported by 
Regulatory Science investigations toward 
some generic concerns to the stakeholders. 
In our investigations so far, we have focused 
on potential explanations for differences in 
drug exposure, which are occasionally ob-
served or suspected in individual patients 
upon switching from a brand- name drug 
to a generic drug. Furthermore, we also 
looked into concerns about generic- generic 
drug interchangeability. Such generic- 
generic switching occurs very frequently in 
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the Netherlands, and drift of the exposure 
upon switching between generics has been 
postulated.5
AWARENESS OF PHARMACOKINETIC 
VARIABILITY
In light of the sometimes reported differ-
ences in exposure after switching from a 
brand- name drug to a generic drug, we 
investigated whether such differences in 
drug exposure observed in individual pa-
tients may be due to either a difference be-
tween the drug formulations (i.e., generic 
and brand- name drugs), or to intrasubject 
PK variability of the active substance.1 For 
that purpose, replicate design bioequiva-
lence studies of various registered drugs 
(for drugs involved see Table 1) were re-
analyzed with respect to intrasubject vari-
ability in total and peak drug exposure 
(i.e., area under the curve (AUC) and peak 
plasma concentration (Cmax)) for both 
generic and the brand- name drugs and 
also the variance related to the subject- by- 
formulation interaction.
Results showed that the intrasubject 
PK variability (in AUC from time zero 
to the last sampling time point (AUC0-t) 
and Cmax) was generally comparable for 
the brand- name drug and the generic drug 
(see Table 1). Differences in exposure 
caused by subject- by- formulation inter-
action were considered negligible in the 
investigated bioequivalence studies. This 
indicates that the variability in drug expo-
sure is generally not affected by the drug 
formulation. Furthermore, the variabil-
ity in exposure upon switching between 
the generic and the brand- name drug was 
comparable with that observed for brand- 
name drugs (or likewise for the generic 
drugs) after repeated administrations. This 
clearly shows that the variation in drug 
exposure upon switching between generic 
and brand- name drugs is the same as when 
Table 1 Estimation of intrasubject variances and variance due to subject- by- formulation interaction for AUC0-t and Cmax in 
individuals in the investigated studies.
Active substances 
(strength) Ratios N












R2- R1 25 0.02 0.14 −0.069 −0.07 0.16 −0.042 
T2- T1 26 −0.11 0.23 −0.01 0.18
T- R 25 −0.04 0.12 −0.09 0.13
Alendronate 
(70 mg)
R2- R1 68 −0.04 0.24 0.047 −0.14 0.29 0.021 
T2- T1 67 0.01 0.22 0.01 0.27
T- R 67 0.01 0.28 −0.04 0.30
Atorvastatine 
(40 mg)
R2- R1 54 0.10 0.05 −0.015 −0.06 0.18 −0.091 
T2- T1 58 0.13 0.06 0.22 0.33
T- R 54 −0.04 0.04 0.02 0.16
Cyclosporine 
(100 mg)
R2- R1 133 0.02 0.04 −0.006 −0.02 0.17 −0.026 
T2- T1 134 0.02 0.03 0.03 0.16
T- R 133 0.03 0.03 0.03 0.14
Exemestane 
(25 mg)
R2- R1 54 −0.02 0.02 −0.008 −0.03 0.09 −0.007 
T2- T1 54 −0.00 0.02 0.07 0.08
T- R 54 0.04 0.01 0.01 0.08
Mycophenolate 
mofetil (250 mg)
R2- R1 37 0.00 0.01 −0.003 0.05 0.14 −0.029 
T2- T1 37 −0.03 0.02 0.01 0.10
T- R 37 −0.01 0.01 0.01 0.09
Mycophenolate 
Mofetil (500 mg)
R2- R1 41 −0.00 0.03 0.002 0.11 0.20 −0.038 
T2- T1 40 −0.04 0.01 −0.06 0.10
T- R 40 −0.01 0.02 −0.01 0.11
Ropinirole (2 mg) R2- R1 33 −0.01 0.01 0.000 0.04 0.02 0.009 
T2- T1 29 0.01 0.02 0.14 0.08
T- R 28 −0.07 0.02 0.14 0.06
Adapted with permission from Yu et al.5 ©2015 The British Pharmacological Society.
Variances of subject- by- formulation interaction for both AUC0-t and Cmax are relatively small (i.e., < 0.05) and most of them are negatively estimated by the Method 
of Moment, indicating that they are close to zero. The small variances of subject- by- formulation interaction indicate that the difference in drug exposure upon 
switching from brand- name to generic drug is very similar to repeated administration of the same drug for individual subjects in the investigated studies.
AUC0-t, area under the drug concentration-time curve from time zero to the last sampling time point; Cmax, peak plasma concentration; R, reference formulation; 
R1, reference formulation in first administration in replicate design study; R2, reference formulation in second administration in replicate design study SbyF 
interaction, subject- by- formulation interaction; T, generic test formulation; T1, generic test formulation in first administration in the replicate design study; T2, 
generic test formulation in second administration in replicate design study.
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repeating the same drug (either generic 
drug or the brand- name drug) among the 
investigated drugs in the study. Therefore, 
the anecdotal differences in drug exposure 
(either increased or decreased) that have 
been reported or hypothesized in litera-
ture upon switching from the brand- name 
to generic drug, are likely to be caused by 
the intrasubject variability in exposure of 
the active substance, and, therefore, not a 
solid marker for a systematic difference in 
clinical pharmacology of the generic drug.
GENERIC- GENERIC SUBSTITUTION
To evaluate the interchangeability be-
tween different generic drugs, we con-
ducted a comparative exposure clinical 
trial using gabapentin as a test medicine.5 
The trial compared the PK of three reg-
istered generic drugs of gabapentin and 
the European brand- name drug Neurotin 
(Pfizer B.V., Capelle a/d IJssel, The 
Netherlands). The results showed that 
the three generic gabapentin drugs are 
bioequivalent with each other, indicating 
that the potential drifting effect for these 
generic gabapentin drugs is small, and the 
drugs can be considered interchangeable. 
This finding provided the first evidence 
that bioequivalence between different ge-
neric drugs occurs, despite the fact that 
direct demonstration of bioequivalence 
has not been requested upon registration. 
In our opinion, this result could have been 
expected because all registered generic 
drugs have been demonstrated to be bio-
equivalent to the brand- name drug (i.e., 
B = A and C = A) and the ratio of expo-
sure between the brand- name and the ge-
neric drugs is close to 1 (100%). Therefore, 
the probability of generic drugs not being 
bioequivalent (i.e., B ≠ C) is small. In order 
to further substantiate this hypothesis, we 
have investigated bioequivalence between a 
broad range of generic drugs in an indirect 
comparison, encompassing 120 bioequiva-
lence studies.5 The study results indicated 
that in the majority of cases (within 80.5% 
of the generic- generic substitution cases the 
90% confidence interval for both AUC0-t 
and Cmax being within the acceptance 
range of 80–125%), bioequivalence was in-
dicated. In 90.1% and 87.0% of the cases, 
this was the case for either AUC0-t or Cmax, 
respectively. In case the 80–125% criterion 
was not met, in only 3% of the cases, the 
border of the 90% confidence interval was 
outside a wider 75–133% range.5 Although 
these results cannot fully exclude the possi-
bility of nonbioequivalence upon generic- 
generic drug substitution, we consider that 
a pronounced risk on relevant differences 
in exposure upon generic- generic substitu-
tion in clinical practice is unlikely.
THE FUTURE
In general, generic drugs are quite easily 
blamed if efficacy is not reached or an ad-
verse event is observed. Healthcare provid-
ers tend to focus on the assumed potentially 
different quality of generic drugs, however, 
they often forget about the uncertainty in 
medications, brand- name as well as generic 
drugs, in general, and the diversity of indi-
vidual patients. After the Hatch- Waxman 
Act in 1984, in which the regulation of ge-
neric drugs was introduced in the United 
States, generic drugs have now been used 
for > 30 years. Although discussion about 
effectiveness and safety of generic drugs 
continues, in this long period, no apparent 
trend or solid evidence was identified to 
confirm that generic drugs are not as good 
as claimed. Based on our investigations, as 
summarized above, we consider that dif-
ferent drug concentrations in individual 
subjects between generic and brand- name 
drugs does not necessarily indicate non-
bioequivalence. Instead, the difference in 
concentration is likely to be mainly due to 
the intrasubject variability of PK of the ac-
tive substance. In addition, no major issues 
were identified upon generic- generic sub-
stitution as compared with the branded- 
generic substitution.
In general, Regulatory Science activi-
ties may play a role in scrutinizing current 
requirements for generic drug approval 
with respect to bioequivalence in order 
to ascertain therapeutic equivalence be-
tween the generic and brand- name drugs. 
Besides technical regulatory aspects, also 
aspects like communication and educa-
tion, adherence, shape, and color of the 
products may be considered with the 
aim to see at what point improvements 
may be obtained in the field of generic 
switching. For example, the principles 
of generic drugs may not always be suf-
ficiently transparent to all stakeholders. 
Therefore, in order to improve clarity on 
the assumptions and extrapolations used 
in regulation requirements toward gener-
ics, ongoing efforts to build and maintain 
confidence in generic drugs by means of 
providing good communication, sup-
ported by sound regulatory science data, 
as well as a reliable and scrutinized regula-
tory system are essential.
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